Where does Sanofi Biotechnology rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Sanofi Biotechnology ranks #9,116 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Sanofi Biotechnology hold?

Sanofi Biotechnology holds 35 US utility patents granted between 2017 and 2025, spanning 13 technology areas.

What is Sanofi Biotechnology's Innovation Score?

Sanofi Biotechnology has an Innovation Score of 47.6 out of 100 (top 18% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Sanofi Biotechnology focus on?

Sanofi Biotechnology's top technology area is C07K (PEPTIDES) with 35 patents. Grants appear in 13 CPC subclasses total.

Is Sanofi Biotechnology's patent grant rate increasing or decreasing?

Sanofi Biotechnology's recent grant velocity is +91% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Sanofi Biotechnology's patents?

Sanofi Biotechnology's patents average 23.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Sanofi Biotechnology patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Sanofi Biotechnology

USPTO PatentsView assignee record - 35 granted patents across 13 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (PEPTIDES).

Compiled by PlainPatent · May 15, 2026

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Sanofi ranks #9,116 of 50,000 tracked US assignees by granted-patent volume, with 35 patents across 13 technology areas.

#9,116
of 50,000 US assignees by volume: Top 18%
by Innovation Score (47.6/100): 23.4
avg claims per patent: +91%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R9116 · Foreign Corporation #9,116 · 35 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 35 grants
UPPER-Q #9,116/50,000
PHOTO-FINISH Reciprocal Labs
CPC-FOCUS C07K · 13 areas
INNOV-PAR 47.6/100
CLAIMS-DENSE 23.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +91% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Reciprocal Labs Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Cybereason · near

48
FPT Industrial S p a · near

48
Qliktech Internation… · near

48
Sanofi Biotechnology · this assignee

48
Short Brothers · near

48
3D Lighting Innovati… · lowest

7

What this shows Sanofi Biotechnology stamps GRANTS-SMALL, UPPER-Q, PHOTO-FINISH, CPC-FOCUS, INNOV-PAR, CLAIMS-DENSE, TYPE-FRNCORP, VEL-SURGE, BOOK-FULL. Volume places it #9,116 of 50,000; Innovation Score 47.6/100 sits in the top 18% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is Reciprocal Labs Corporation (±0 grants).

Portfolio overview

Sanofi Biotechnology has been granted 35 US utility patents between 2017 and 2025, placing Sanofi Biotechnology at #9,116 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 13 distinct Cooperative Patent Classification (CPC) subclasses, averaging 23.4 claims per patent with primary concentration in C07K (PEPTIDES). As a Foreign Corporation, Sanofi Biotechnology is one of the more focused assignees in the PatentsView dataset. By volume, Sanofi sits between Reciprocal Labs Corporation (35 patents, rank #9,110) and Showa Glove Co. (35 patents, rank #9,118) - the closest US assignees by grant volume. The composite Innovation Score of 47.6/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 21 grants, compared with 11 in the 2015–2019 window, a +91% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Sanofi Biotechnology's 23.4 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 13 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Reciprocal Labs

35
Robert Welch Desi…

35
Robotic Research…

35
S I P A Societa'…

35
Scinopharm Taiwan

35
Seikoh Giken

35
Shannon Systems

35
Showa Glove

35
Sanofi Biotechnol… ◀

35

What this shows Sanofi holds 35 patents at rank #9,114, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Sanofi

By rank, the assignees closest to #9,114 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Sanofi's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Sanofi, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (48 here).

FPT Industrial S.p.a 48 Short Brothers Plc 48 Qliktech International AB 48 Cybereason Inc. 48

Sanofi's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

48 Top 18% higher than 82% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Sanofi Biotechnology patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	3	8.6%
2018	4	11.4%
2019	4	11.4%
2020	1	2.9%
2021	6	17.1%
2022	6	17.1%
2023	4	11.4%
2024	4	11.4%
2025partial year	3	8.6%

Which technologies does Sanofi Biotechnology patent most?

C07K - PEPTIDES 35

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 34

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 33

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 4

A61J - CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE 4

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 4

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 3

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 2

C22F - CHANGING THE PHYSICAL STRUCTURE OF NON-FERROUS METALS AND NON-FERROUS ALLOYS 1

C22C - ALLOYS 1

B21J - FORGING; HAMMERING; PRESSING METAL; RIVETING; FORGE FURNACES 1

B21D - WORKING OR PROCESSING OF SHEET METAL OR METAL TUBES, RODS OR PROFILES WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL 1

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 1

Top 13 of 13 technology areas

Where it ranks

Overall rank by patents

#9,116

of 50,000 tracked assignees

Innovation Score

47.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.